Resolutions from the Annual General Meeting 2026

Core Points - The Annual General Meeting of Novonesis (Novozymes A/S) was held, resulting in several key resolutions regarding the company's governance and financial distributions [1][3]. Group 1: Board of Directors and Committees - The composition of the Board of Directors and its committees was confirmed, with re-elections for key positions including Cornelis (Cees) de Jong as Chair and Heine Dalsgaard as Vice Chair [3][4]. - The Board of Directors includes members such as Lise Kaae, Monila Kothari, Kasim Kutay, Kevin Lane, Morten Otto Alexander Sommer, and Kim Stratton, among others [4]. Group 2: Financial Approvals - The audited Annual Report for 2025 was approved, along with a profit distribution that includes an ordinary dividend of DKK 4.25 (approximately EUR 0.57) per A and B share, and an interim dividend of DKK 2.25 (approximately EUR 0.3) disbursed on August 27, 2025 [3]. - The Remuneration Report for 2025 was approved in an advisory vote, and the remuneration for the Board of Directors for 2026 was also approved [3]. Group 3: Authorizations and Proposals - The Board of Directors received renewed authorizations to implement capital increases, acquire treasury shares, and distribute extraordinary dividends [3]. - A shareholder proposal was withdrawn during the meeting [3].